In addition, other dual agonists (GLP-1RA and glucagon receptor agonists, such as oxyntomodulin) or triple agonists (GIP/GLP-1/glucagon receptor agonists, such as YAG-glucagon) are in development for the treatment of T2DM [268]. This evidence concerns the gene GIP and type 2 diabetes mellitus.